Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes

Han, Seung Jin; Kim, Hae Jin; Choi, Sung‐E; Kang, Yup; Lee, Kwan Woo; Kim, Dae Jung

doi:10.1016/j.diabres.2010.06.004

Cited by 17 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total GIP was measured by antiserum R65 in 12 of the articles, by the ELISA kit (Millipore Corporation, Billerica, MA) in 7 articles, by the radioimmunoassay kit from (RIA kit; Phoenix Laboratories, Belmont, CA) in 2 articles, and by antibody S705, which recognizes 5-kD GIP, in 1 article. After contact with corresponding authors of retrieved articles, we received additional data that were not described in the published reports from four of the included trials (12,14,18,25). The included studies reported total GIP plasma responses from 15 OGTTs (one 25-g OGTT, one 40-g/m 2 OGTT, four 50-g OGTTs, eight 75-g OGTTs, and one 125-g OGTT) and 13 mixed-meal tests (12 solid mixed-meal tests and 1 liquid mixed-meal test), ranging from 300 kcal to 833 kcal.…”

Section: Resultsmentioning

confidence: 99%

“…Subgroup 1 included trials with participants with mean BMI <30 kg/m 2 (6,11,14,17,20,24); subgroup two included trials with participants with mean BMI ≥30 kg/m 2 (13,15,18,19,21,23,25–30). …”

Section: Resultsmentioning

confidence: 99%

“…Another strength of the present approach is that data obtained using a broad spectrum of assays for the measurement of total GIP levels were included. Also, we were able to obtain unpublished data from four trials (12,14,18,25), which also added power to our analyses.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna¹,

et al. 2013

View full text Add to dashboard Cite

OBJECTIVETo investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients with type 2 diabetes and nondiabetic control subjects during oral glucose or meal tests.RESEARCH DESIGN AND METHODSEligible trials were identified by The Cochrane Library, MEDLINE, Embase, and Web of Science. Data were retrieved and random-effects models for the primary meta-analysis, random-effects meta-regression, and subgroup and regression analyses were applied.RESULTSRandom-effects meta-analysis of GIP responses in 23 trials during 28 different stimulation tests showed that patients with type 2 diabetes (n = 363) exhibited no significant differences (P = not significant) in peak plasma GIP, total area under the curve (tAUC), time-corrected tAUC (tAUC × min−1), and time-corrected incremental area under the curve (iAUC × min−1) in comparison with nondiabetic control subjects (n = 325) but had lower GIP responses as evaluated from iAUC (weighted mean difference, −648 pmol/L × min; 95% CI, −1,276 to −21). Fixed-effects models meta-analyses confirmed most of the results of the primary meta-analysis but showed iAUC × min−1 to be reduced and showed tAUC and tAUC × min−1 to be higher in diabetic patients. Random-effects meta-regression of the primary meta-analysis showed that age (peak GIP, tAUC, iAUC, and iAUC × min−1), BMI (tAUC, iAUC, and iAUC × min−1), and HbA1c (iAUC and iAUC × min−1) predicted some of the GIP outcomes. Post hoc subgroup analysis showed a negative influence of age and of HbA1c on GIP responses and showed a positive influence of BMI on GIP responses.CONCLUSIONSOur results suggest that patients with type 2 diabetes are characterized by preserved GIP secretion in response to oral glucose and meal tests. They also suggest that high BMI is associated with increased GIP responses but increasing age and HbA1c are associated with reduced GIP secretion.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna¹,

et al. 2013

View full text Add to dashboard Cite

show abstract

“…We excluded studies which used non-specific assays that cross-react with the major proglucagon fragment [2, 10–12], those which did not provide enough data [13] and those which dealt with intact GLP-1 only [14–19]. Excluded trials were listed with the reason for exclusion.…”

Section: Methodsmentioning

confidence: 99%

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

et al. 2013

View full text Add to dashboard Cite

Aims/hypothesis We carried out a systematic review of clinical studies investigating glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes and non-diabetic controls and performed meta-analyses of plasma total GLP-1 concentrations during an OGTT and/or meal test. Methods Random effects models for the primary meta-analysis and random effects meta-regression, subgroup and regression analyses were applied. Results Random effects meta-analysis of GLP-1 responses in 22 trials during 29 different stimulation tests showed that patients with type 2 diabetes (n=275) and controls without type 2 diabetes (n=279) exhibited similar responses of total GLP-1 (p=NS) as evaluated from peak plasma concentrations (weighted mean difference [95% CI] 1.09 pmol/l [−2.50, 4.67]), total AUC (tAUC) (159 pmol/l×min [−270, 589]), time-corrected tAUC (tAUC min−1) (0.99 pmol/l [−1.28, 3.27]), incremental AUC (iAUC) (−122 pmol/l×min [−410, 165]) and time-corrected iAUC (iAUC min−1) (−0.49 pmol/l [−2.16, 1.17]). Fixed effects meta-analysis revealed higher peak plasma GLP-1 concentrations in patients with type 2 diabetes. Subgroup analysis showed increased responses after a liquid mixed meal test (peak, tAUC and tAUC min−1) and after a 50 g OGTT (AUC and tAUC min−1), and reduced responses after a solid mixed meal test (tAUC min−1) among patients with type 2 diabetes. Meta-regression analyses showed that HbA1c and fasting plasma glucose predicted the outcomes iAUC and iAUC min−1, respectively. Conclusions/interpretation The present analysis suggests that patients with type 2 diabetes, in general, do not exhibit reduced GLP-1 secretion in response to an OGTT or meal test, and that deteriorating glycaemic control may be associated with reduced GLP-1 secretion.

show abstract

“…Some studies found an increased DPP-4 activity in T2D vs. control subjects and a direct correlation with haemoglobin A1c (HbA1c) [3,4]. Some studies found an increased DPP-4 activity in T2D vs. control subjects and a direct correlation with haemoglobin A1c (HbA1c) [3,4].…”

Section: Introductionmentioning

confidence: 99%

The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients

Fadini

Albiero

Menegazzo

et al. 2012

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes

Cited by 17 publications

References 17 publications

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients

Contact Info

Product

Resources

About